Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
MALVERN, PA — February 10, 2011 — Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Jour…